Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis

被引:18
作者
van Boxel-Dezaire, AHH
Smits, M
van Trigt-Hoff, SCJ
Killestein, J
van Houtwelingen, JC
Polman, CH
Nagelkerken, L
机构
[1] TNO Prevent & Hlth, Div Infect Dis & Immunol, NL-2301 CE Leiden, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Neurol, NL-1007 MB Amsterdam, Netherlands
[3] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands
关键词
MS; clinical subtypes; cytokines;
D O I
10.1016/S0165-5728(01)00398-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Little is known about the involvement of cytokines in the pathogenesis of primary progressive (PP) multiple sclerosis (MS). We evaluated in this cross-sectional study whether IL-18, IL-12p35, IL-12p40, TNF-alpha, IFN-gamma, IL-10, IL-4, TGF-beta, IL-12R beta1, and IL-12R beta2 mRNA expression in unstimulated white blood cells showed significant differences between relapsing-remitting (RR), secondary progressive (SP) and PP MS patients, and healthy controls. All clinical subtypes showed unique mRNA expression patterns as compared to the controls. Both RR and SP patients displayed increased levels of IL-12p40, IL-18, and TGF-beta mRNA compared to controls, whereas PP patients showed only increased IL-18 mRNA levels. Both in PP and SP patients, IFN-gamma and IL-10 mRNA were decreased compared to RR patients and controls. PP patients were unique in that they showed decreased IL-12R beta1 mRNA. In conclusion, our data show that the assessment of cytokine (receptor) mRNA profiles is useful to discriminate between the different clinical subtypes and suggest that different cytokines are involved in the pathogenesis of PP MS as compared to RR and SP MS. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:152 / 160
页数:9
相关论文
共 41 条
[21]   A COMPARISON OF THE PATHOLOGY OF PRIMARY AND SECONDARY PROGRESSIVE MULTIPLE-SCLEROSIS [J].
REVESZ, T ;
KIDD, D ;
THOMPSON, AJ ;
BARNARD, RO ;
MCDONALD, WI .
BRAIN, 1994, 117 :759-765
[22]   Selective expression of an interleukin-12 receptor component by human T helper 1 cells [J].
Rogge, L ;
BarberisMaino, L ;
Biffi, M ;
Passini, N ;
Presky, DH ;
Gubler, U ;
Sinigaglia, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (05) :825-831
[24]   IDENTIFICATION OF LYMPHOTOXIN AND TUMOR-NECROSIS-FACTOR IN MULTIPLE-SCLEROSIS LESIONS [J].
SELMAJ, K ;
RAINE, CS ;
CANNELLA, B ;
BROSNAN, CF .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (03) :949-954
[25]   Spinal cord atrophy and disability in MS - A longitudinal study [J].
Stevenson, VL ;
Leary, SM ;
Losseff, NA ;
Parker, GJM ;
Barker, GJ ;
Husmani, Y ;
Miller, DH ;
Thompson, AJ .
NEUROLOGY, 1998, 51 (01) :234-238
[26]   IL-4 INDUCES ALLERGIC-LIKE INFLAMMATORY DISEASE AND ALTERS T-CELL DEVELOPMENT IN TRANSGENIC MICE [J].
TEPPER, RI ;
LEVINSON, DA ;
STANGER, BZ ;
CAMPOSTORRES, J ;
ABBAS, AK ;
LEDER, P .
CELL, 1990, 62 (03) :457-467
[27]   MAJOR DIFFERENCES IN THE DYNAMICS OF PRIMARY AND SECONDARY PROGRESSIVE MULTIPLE-SCLEROSIS [J].
THOMPSON, AJ ;
KERMODE, AG ;
WICKS, D ;
MACMANUS, DG ;
KENDALL, BE ;
KINGSLEY, DPE ;
MCDONALD, WI .
ANNALS OF NEUROLOGY, 1991, 29 (01) :53-62
[28]  
Tsunoda I, 2000, BRAIN PATHOL, V10, P402
[29]  
van Boxel-Dezaire AHH, 1999, ANN NEUROL, V45, P695, DOI 10.1002/1531-8249(199906)45:6<695::AID-ANA3>3.0.CO
[30]  
2-R